The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
J Qu, Q Mei, L Liu, T Cheng, P Wang… - … in medical oncology, 2021 - journals.sagepub.com
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
J Qu, Q Mei, L Liu, T Cheng, P Wang… - … Advances in Medical …, 2021 - europepmc.org
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
[HTML][HTML] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
J Qu, Q Mei, L Liu, T Cheng, P Wang… - … Advances in Medical …, 2021 - ncbi.nlm.nih.gov
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
J Qu, Q Mei, L Liu, T Cheng, P Wang… - Therapeutic …, 2021 - pubmed.ncbi.nlm.nih.gov
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
[PDF][PDF] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
J Qu, Q Mei, L Liu, T Cheng, P Wang, L Chen, J Zhou - 2021 - researchgate.net
Abstract The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand
1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of …
1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of …
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
J Qu, Q Mei, L Liu, T Cheng, P Wang… - Therapeutic …, 2021 - search.ebscohost.com
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
J Qu, Q Mei, L Liu, T Cheng, P Wang… - Therapeutic …, 2021 - search.ebscohost.com
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …